U.S. markets closed
  • S&P Futures

    4,394.00
    -0.50 (-0.01%)
     
  • Dow Futures

    34,933.00
    -20.00 (-0.06%)
     
  • Nasdaq Futures

    14,936.75
    -11.00 (-0.07%)
     
  • Russell 2000 Futures

    2,193.20
    +6.50 (+0.30%)
     
  • Crude Oil

    72.15
    +0.50 (+0.70%)
     
  • Gold

    1,802.20
    +2.40 (+0.13%)
     
  • Silver

    24.76
    +0.12 (+0.47%)
     
  • EUR/USD

    1.1823
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.2340
    -0.0420 (-3.29%)
     
  • Vix

    19.36
    +1.78 (+10.13%)
     
  • GBP/USD

    1.3878
    -0.0001 (-0.01%)
     
  • USD/JPY

    109.8100
    +0.0430 (+0.04%)
     
  • BTC-USD

    39,723.10
    +2,754.68 (+7.45%)
     
  • CMC Crypto 200

    931.95
    +55.71 (+6.36%)
     
  • FTSE 100

    6,996.08
    -29.35 (-0.42%)
     
  • Nikkei 225

    27,688.21
    -282.01 (-1.01%)
     

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ChemoCentryx, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2021 - CCXI

·2 min read

New York, New York--(Newsfile Corp. - May 11, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of ChemoCentryx, Inc. (NASDAQ: CCXI).

Shareholders who purchased shares of CCXI during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/chemocentryx-inc-loss-submission-form/?id=15706&from=5

CLASS PERIOD : November 26, 2019 to May 3, 2021

ALLEGATIONS : The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83667